Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer
收藏DataMed2026-07-12 收录
官方服务：
资源简介：
This is a single-center Ib / II study of triple targeted drug combination (endocrine therapy?novel HER2-targeted small molecule inhibitor pyrotinib and CDK4/6 inhibitor dalpiciclib(SHR6390) ) as a first or second line of therapy in patients with relapsed/metastatic hormone receptor positive and HER2-positive breast cancer.
提供机构：
ClinicalTrials.gov
